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Background:  Transforming growth factor-`1 (TGF-`1) is a cytokine with roles in cellular proliferation and pathological fibrosis. A latent form of 
TGF-`1is present in high concentrations in platelets. We recently reported that latent TGF-`1 can be activated by shear in vitro and in a mouse 
model of thrombosis. Thus, TGF-`1 may contribute to the pathophysiology of conditions with elevated shear, such as aortic stenosis (AS).
Methods:  Blood was drawn from 15 patients with AS and 32 controls undergoing cardiac catheterization. Samples were tested for total and active 
TGF-`1 levels by ELISA.
Results:  There were no differences between AS patients and controls by sex, medication use, coronary artery disease, or ejection fraction (all 
p>0.05). AS patients were older (71 vs. 63 years, p = 0.01). Median TGF-`1 levels were 1.2 ng/mL in patients and 0.95 ng/mL in controls (p=0.06). 
7/15 AS patients had detectable levels of active TGF-`1, as compared with 1/32 controls (median 0.002 vs 0 ng/mL, p<0.01, Figure 1). The lone 
control with measurable active TGF-`1 had acute thrombotic peripheral vascular disease.
Conclusion: A higher percentage of AS patients have detectable plasma levels of TGF-`1 than cardiac catheterization controls. These data are 
consistent with a model in which increased shear forces result in systemic TGF-`1 activation, which in turn may lead to AS progression by stimulating 
valve fibrosis. 
